Pak Bun Healthcare (02293.HK) Hot Stock Analysis

Pak Bun Healthcare (02293.HK) is a Hong Kong-based healthcare enterprise primarily providing medical staffing solutions[1]. On December 22, 2025, the company was listed on the Hong Kong Stock Surge List of the East Money App due to winning the ‘2025 Listed Company of the Year Award’ issued by the Hong Kong Stock Analysts Association on December 11, 2025[2]. As of December 24, 2025, the company’s stock closed at HK$0.500, close to its 52-week low of HK$0.490, a decrease of 1.96% from the previous trading day[1], with a market capitalization of approximately HK$201 million[1].

The company’s financial performance is under pressure. For the fiscal year 2025 (ending June 30), its revenue decreased by 21.5% year-on-year, and net profit decreased by 43.3% year-on-year[3]. Nevertheless, the company’s current dividend yield reaches 7.84%, which has certain appeal to income-oriented investors[1]. From the trading perspective, the daily trading volume of the company’s stock was only 4,000 shares, far below the average volume of 41,186 shares[1], indicating low market participation, and price fluctuations may be affected by short-term speculative behavior.

1. Event-driven Popularity
   : The company’s stock price entered the hot list driven by the award announcement event, but the popularity did not translate into substantial buying support. The low trading volume indicates that the market remains cautious about the company’s long-term prospects.
2. Contradiction Between Finance and Valuation
   : The high dividend yield contradicts the declining profits; attention needs to be paid to the sustainability of future dividends.
3. Prominent Liquidity Risk
   : Extremely low trading volume may lead to sharp fluctuations in stock prices, making it difficult for investors to enter and exit the market.

• Financial Risk
  : Revenue and net profit continue to decline, and business growth faces challenges[3].
• Liquidity Risk
  : Trading volume is far below the average level, stock prices are easily affected by speculative funds, and liquidity is insufficient[1].
• Valuation Risk
  : Declining profits may affect the sustainability of dividends; the current high dividend yield may not have long-term support[1].

• Award Recognition
  : The award from the Hong Kong Stock Analysts Association affirms the company’s operating performance and may bring positive impacts to its future development[2].

Pak Bun Healthcare (02293.HK) recently became a popular Hong Kong stock due to winning an industry award, but its stock price performance is close to the 52-week low with sluggish trading volume. The company’s financial performance has declined, but its dividend yield is relatively high, and there are risks in profit sustainability and liquidity. Investors need to pay attention to key factors such as the company’s future business growth, dividend policy, and changes in trading volume.